DevvStream Corp. (DEVS) Stock Tumbles 68% After-Hours: Here Is What Is Going On - DevvStream (NASDAQ:DEVS

DevvStream’s Form 8-K says it received fairness opinions for the proposed three-party combination with XCF Global and Southern Energy Renewables. It also states the prior DevvStream–Southern merger agreement automatically terminated after required fairness opinions were received, as a contractual step under the April 13, 2026 Business Combination Agreement. The parties say the BCA remains in force and they expect to file an S-4 with the SEC in coming weeks.

DevvStream (DEVS), XCF Global (SAFX) and Southern Energy Renewables said the three-party business combination agreement remains in effect after media mischaracterized an SEC Form 8-K. They said fairness opinions were received and the prior merger agreement automatically terminated under the BCA. The parties expect to file an S-4 in coming weeks to seek shareholder approvals.

UniQure (QURE) submitted a Biologics License Application to the FDA for AMT-130, a gene therapy for Huntington's disease, seeking accelerated approval. The submission is supported by three-year data showing slowed disease progression. The company also filed a similar application with the U.K.'s MHRA. QURE stock is up 6.04% in pre-market trading.

Ford and GM will face tariffs on cars made in Canada due to U.S. tariffs on Canadian goods. Canada's retaliation, effective September 8, may impact housing costs. Ford is up 4.8% YTD but down 3.12% in the past month, while GM is up nearly 7% YTD but down 1.22% in the past month. Both companies may revise earnings guidance.

The FTC and 22 states sued Amazon, alleging it overcharged advertisers in search auctions for over 7 years, using undisclosed markups. Amazon reportedly converted second-price auctions to first-price, increasing advertiser costs. The suit claims Amazon concealed the changes, generating billions in revenue. Affected advertisers include over 500,000 small and medium-sized businesses.

Taiwan's FDA issued a red alert over a heart pump device after the U.S. FDA warned of a defect in Abiomed Inc.'s Automated Impella Controllers, linked to 3 deaths and 37 injuries. The device, used in 19 Taiwanese hospitals, is being recalled for a cartridge recognition issue. Johnson & Johnson MedTech, the local license holder, must notify providers and implement fixes.